Diacerein: Recent insight into pharmacological activities and molecular pathways

Biomed Pharmacother. 2020 Nov:131:110594. doi: 10.1016/j.biopha.2020.110594. Epub 2020 Aug 25.

Abstract

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) and the active metabolite is rhein. It is a non-steroidal anti-inflammatory drug with unique pharmacological properties as anti-oxidant and anti-apoptosis. Diacerein has recently shown to have a potential role by mediating anti-inflammatory as well as anti-oxidant and anti-apoptosis in kidney injury, diabetes mullites, and a beneficial effect on pain relief. It may have a therapeutic role in cancer, ulcerative colitis, testicular injury and cervical hyperkeratosis. Furthermore, diacerein has a valuable addition in combination therapy as a synergetic agent. This review, the first of its kind, highlights the proposed roles of diacerein in osteoarthritis and discusses recent results supporting its emerging roles with a particular focus on how these new insights may facilitate the rational development of diacerein for targeted therapies in the future.

Keywords: Anti-apoptosis; Anti-inflammatory; Anti-oxidant; Cytokines; Diacerein.

Publication types

  • Review

MeSH terms

  • Animals
  • Anthraquinones / pharmacology*
  • Anthraquinones / therapeutic use
  • Anti-Inflammatory Agents / pharmacology*
  • Anti-Inflammatory Agents / therapeutic use
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / metabolism
  • Gastrointestinal Diseases / drug therapy
  • Gastrointestinal Diseases / metabolism
  • Humans
  • Inflammation Mediators / antagonists & inhibitors*
  • Inflammation Mediators / metabolism*
  • Kidney Diseases / drug therapy
  • Kidney Diseases / metabolism
  • Osteoarthritis / drug therapy
  • Osteoarthritis / metabolism
  • Signal Transduction / drug effects*
  • Signal Transduction / physiology

Substances

  • Anthraquinones
  • Anti-Inflammatory Agents
  • Inflammation Mediators
  • diacerein